Hepatotoxicity induced by alendronate therapy

被引：23
作者：
Yanik, B.
Turkay, C.
Atalar, H.
机构：
[1] Fatih Univ, Sch Med, Dept Phys Med & Rehabil, Ankara, Turkey
[2] Fatih Univ, Sch Med, Dept Internal Med, Gastroenterol Sect, Ankara, Turkey
[3] Fatih Univ, Sch Med, Dept Orthoped & Traumatol, Ankara, Turkey
来源：
OSTEOPOROSIS INTERNATIONAL | 2007年 / 18卷 / 06期
关键词：
adverse effects; alendronate; osteoporosis;
D O I：
10.1007/s00198-007-0323-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Here we describe a 47-year-old postmenopausal woman who had been taking alendronate 70 mg/week for osteoporosis. After two months of alendronate therapy, she developed hepatotoxicity, and no other etiological factors for this besides the alendronate were apparent. After the alendronate therapy was discontinued, the patient's hepatic enzyme levels slowly returned to normal. Hepatotoxicity due to alendronate therapy is a rare but possible adverse effect.
引用
收藏
页码：829 / 831
页数：3
相关论文
共 16 条
[1]  
Carrère C, 2002, GASTROEN CLIN BIOL, V26, P179
[2]   Alendronate-induced auditory hallucinations and visual disturbances [J].
Coleman, CI ;
Perkerson, KA ;
Lewis, A .
PHARMACOTHERAPY, 2004, 24 (06) :799-802
[3]  
de La Serna Higuera C, 2001, Gastroenterol Hepatol, V24, P244
[4]   Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study [J].
Eisman, JA ;
Rizzoli, R ;
Roman-Ivorra, J ;
Lipschitz, S ;
Verbruggen, N ;
Gaines, KA ;
Melton, ME .
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (05) :699-705
[5]   Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women [J].
Felsenberg, D ;
Alenfeld, F ;
Beck, O ;
Hammermeister, C ;
Gowan, W .
MATURITAS, 1998, 31 (01) :35-44
[6]  
Ferrari Junior A P, 1998, Sao Paulo Med J, V116, P1882
[7]   Tolerability of once-weekly alendronate in patients with osteoporosis: A randomized, double-blind, placebo-controlled study [J].
Greenspan, S ;
Field-Munves, E ;
Tonino, R ;
Smith, M ;
Petruschke, R ;
Wang, LX ;
Yates, J ;
de Papp, AE ;
Palmisano, J .
MAYO CLINIC PROCEEDINGS, 2002, 77 (10) :1044-1052
[8]  
Halabe A, 2000, NEW ENGL J MED, V343, P365
[9]  
Lieverse RJ, 1998, NETH J MED, V53, P271
[10]  
Maalouf Naim M, 2006, Endocr Pract, V12, P48
12